🫁 Actualización clasificación de TNE pulmonares (IASLC) 🔹 Incorpora Ki-67 como criterio diagnóstico 🔹 Reconoce NET G3 pulmonar 🔹 Transición de “carcinoide” hacia “NET” 🔹 Integra de nuevos conocimientos moleculares 🎯 Más precisión diagnóstica y mejor estratificación 🔗 doi.org/10.1016/j.jtho.2026.…

Save the date! 📅 25 de junio | Madrid 🔬 Actualización práctica sobre ZANOSAR® en tumores neuroendocrinos 👥 @GCarboneroLab , @JHernando3 y @DrAngelaLamarca 🤝 Con nuestro aval científico @GrupoGetne

See a new #neuroendocrinetumors activity via @PeerView @Ja_Capdevila #MedEd lrn.peerview.com/150211587_1…

#Neuroendocrine carcinoma (NEC) care is advancing. Learn how emerging evidence around DLL3-directed therapies and DLL3/CD3 BiTEs may help shape precision-driven treatment strategies and improve patient outcomes: bit.ly/40m8aY9 #Oncology #MedEd @Ja_Capdevila

The RAS revolution continues! Tango Therapeutics' new results date back to the discovery of a synthetic lethal interaction, in 2016: PRMT5 inhibition selectively kills cancer cells deficient in MTAP — about 40% of pancreatic cancer — while ~sparing normal cells This mechanism itself is probably independent of RAS, but given RAS inhibition is the likely future foundation of therapy, Tango's PRMT5 inhibitor, Vopimetostat, was tested in combination with RevMed's RAS inhibitor, Daraxonrasib — in MTAP-deficient pancreatic cancer Today's data come from a small number of patients, but the 6-month progression-free survival was 90% (compared, cross-trial, with Daraxonrasib alone, ~56%)

Last year, we reported that KRAS PRMT5 is synergistic in MTAP-null PDAC (doi.org/10.1158/0008-5472.CA…). Today, the first clinical data for a KRAS/PRMT5 combination was reported, with an incredible 92% ORR. RAS inhibitors are the present, but combinations are the future!! $TNGX $RVMD

Daraxonrasib #PancreaticCancer data is a major step, but skin toxicity limits dosing. Timely 4-step algorithm in @OncJournal protects patient QoL & treatment continuity. academic.oup.com/oncolo/adva… #OncoTwitter #PancreaticCancer #Oncology #SupportiveCare

🧬 REGETNE-tiroides: RWE en CAT (n=214) 📈 mOS: 4.5 meses 🧪 Perfil molecular: mejor SG 🧪 BRAF V600E: mejor pronóstico 🧪 TERTp: peor pronóstico 🎯 IO, TKI, IO TKI y terapias dirigidas: mayor supervivencia. ⚠️ Tratamiento local: impacto pronóstico, incluso en enfermedad M1 🔗 doi.org/10.1093/oncolo/oyag1…

Honored to have participated in the Revolution RAS-302 clinical trial that demonstrated 60% overall survival for patients who received the KRAS on inhibitor #Daraxonrasib compared to chemotherapy. Our team @panoncology participated in this practice changing clinical trial in 🇵🇷 Puerto Rico. We are grateful to @RevMedicines and their leaders, scientists Dr Jan Smith, Dr. Wang, Dr. Salman, and oncologists Miguel Colon Donate, Karina Arocho, Luis Velazquez, Rafael Perez Casellas, Santa Merle, Radiologist Dr. Rafael Vicens and All PanOncology team members. Thank you to our partners Doctor’s Center Hospital Orlando Health and IGM Oncologic Hospital in 🇵🇷 We are privileged to have the trust of our patients, their, families and our colleagues who work together and support clinical trials to advance the science and cure cancer #RAS302 #ClinicalTrials #ASCO26 #PancreasCancer

🚨 FIGHT-302 at #ASCO26 Pemigatinib vs CisGem in 1L FGFR2 rearranged BTC • PFS 8.3 vs 6.8 mo • ORR 47% vs 15% • OS 24.4 vs 25 mo 🤔 Does this change the algorithm or lack of evidence given no IO CisGem? 😯 An option for pts who need response? @_SEOM @atuvibi @GrupoTTD

🚨 PDAC Mini-oral time at #ASCO26 Key takeaway points: • Pembrolizumab does not add efficacy to Olaparib maintenance for gBRACA mutant PDAC. • MEK inh QT (modified GnP) showed promising efficacy (OS 17 mo) -> Will they play a role with KRAS inh? @_SEOM @GrupoTTD @myESMO

New KRAS G12D “Kickers” at #ASCO26 • DN022150 → Refractory PDAC: ORR 40% • GFH375 → Refractory BTC: ORR 40%, PFS 6.2 mo • Toxicity ☢️: RAS(ON) Rash G12D inh. ALT/AST elevations Not ready to dance yet… but definitely warming up! 🔥 @_SEOM @GrupoTTD

Key posters on FGFR2 in BTC: • Mut or ampl seen in ~3% of cases → eligible for targeted FGFR2inh • Tinengotinib shows efficacy in pts pretreated with FGFR2inh • RWD suggest FGFR2inh 1L may deliver better PFS vs CisGem IO. 🕵️‍♂️ results from FIGHT-302. @GrupoTTD #ASCO26

🚨 Genomic profiling in BTC = better outcome prediction: 🔴 KRAS mut → poorer prognosis ❄️ SMAD4 mut → cold microenvironment & weak IO response 🟢BAP1 mut → improved prognosis The future of BTC treatment is biomarker-driven! @atuvibi @GrupoTTD #ASCO26

This is not simply a new pancreatic cancer drug. It is a reminder that even “undruggable” biology can become treatable with persistence. Daraxonrasib doubled median OS vs chemotherapy in RAS G12 metastatic pancreatic cancer: 13.2 vs 6.6 months. A remarkable ASCO moment. #ASCO26 @DrChoueiri @TiansterZhang @CathyEngMD @montypal @tompowles1 @brian_rini @cdanicas @GlopesMd @PGrivasMDPhD @nataliagandur @yekeduz_emre @neerajaiims @ASCO @ONCOassist @OpenMedicineHQ @MedwatchKate @scserendipity1 @CParkMD @urotoday @OncLive @crisbergerot @urologysummit @SuyogCancer @Larvol @IMG_Oncologists

Prime time at #ASCO26 ❗ Daraxonrasib improves PFS and OS in second-line PDAC treatment compared to QT. Grateful to be part of this important moment for patients. Audience on its feet applauding, fully aware of this historic milestone.

Presented at #ASCO26: Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM @ASCO

🔵 #ASCO26 | El Dr. Jaume Capdevila presenta los datos de calidad de vida del estudio COMPETE. ✔️ 177Lu-edotreotide vs everolimus 📈 Mejor HRQoL 📈 Más pacientes con mejoría clínica 📈 Mayor tiempo hasta deterioro 🎯 PRRT mejora la calidad de vida de los pacientes con TNE-GEP.

#ASCO26 This one is special. This is the hottest paper of 2026 and potentially in the history of pancreatic cancer. Let’s dive in. RASolute 302: Daraxonrasib vs investigator’s choice chemotherapy in previously treated metastatic pancreatic cancer Abstract LBA5 (soon!) Presentation: May 31, 2026, 3:21-3:33 PM CDT For decades, pancreatic cancer has been where good ideas go to die. We have optimized chemotherapy. We have sequenced chemotherapy. We have celebrated modest gains. But the central driver of PDAC has always been sitting there in plain sight: RAS. More than 90% of pancreatic cancers have oncogenic RAS mutations, and until recently, we had essentially nothing direct to do about it. Daraxonrasib is an oral RAS(ON) multiselective inhibitor targeting the active GTP-bound state of mutant and wild-type RAS. And in RASolute 302, it delivered. Quick hits: 📌 Phase 3 international randomized trial 500 patients with previously treated mPDAC Daraxonrasib vs investigator’s choice chemotherapy 🧬 RAS G12 population 91.8% of patients had RAS G12 mutations 📈 OS in RAS G12 population 13.2 vs 6.6 months HR 0.40 P<0.001 📈 OS in overall population 13.2 vs 6.7 months HR 0.40 P<0.001 📊 PFS in RAS G12 population 7.3 vs 3.5 months HR 0.45 P<0.001 📊 PFS in overall population 7.2 vs 3.6 months HR 0.49 P<0.001 🔥 12-month OS Overall population: 53.2% vs 17.3% ⚠️ Toxicity matters, but this was not just more efficacy for more toxicity Grade ≥3 AEs: 61.8% vs 69.6% TRAEs leading to discontinuation: 1.2% vs 11.2% This is the kind of survival curve we almost never get to see in pancreatic cancer. This validates RAS(ON) inhibition in the most RAS-addicted major cancer. It takes a target we have talked about for decades and turns it into a clinically meaningful survival benefit in a randomized phase 3 trial. The next questions come fast: 1L combinations, maintenance, perioperative disease, sequencing, resistance, toxicity management, and whether this becomes a new backbone. RAS is here, and it couldn’t have come sooner. nejm.org/doi/full/10.1056/NE… @TheGutonclab @UGrewalMD @TimothyJBrownMD @OncoAlert @Onco_Nexus @ASCO @NazliDizman @LauraAlderMD @DVAraujoMD @DrBarbiOnc @LauraEsfeller @FunchainMD @YGaritaonaindia @DrSAHaddad @jgong15 @iandresmeraz @SakditadMD @RamilaShilpakar @RohitBanwar @lungoncdoc